Catecholamines in the Brain as Mediators of Amphetamine Psychosis

Archives of General Psychiatry

Volumn 27, Issue 2, 1972, Pages 169-179

  Snyder, Solomon H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; BROMIDE; CATECHOLAMINE DERIVATIVE; COCAINE; DOPA; DOPAMINE; DRUG RECEPTOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PHENOTHIAZINE DERIVATIVE; PSYCHEDELIC AGENT;

ADDICTION; ALCOHOL PSYCHOSIS; ANIMAL; BRAIN LEVEL; CAT; COMPULSION; DISEASE MODEL; DRUG EFFECT; HUMAN; ISOMERISM; PAN TROGLODYTES; PARANOID PSYCHOSIS; PSYCHOSIS; RAT; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

AMPHETAMINE; ANIMAL; ANTIDEPRESSIVE AGENTS; BRAIN CHEMISTRY; BROMIDES; CATECHOLAMINES; CATS; COCAINE; COMPULSIVE BEHAVIOR; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; DOPAMINE; HALLUCINOGENS; HUMAN; ISOMERISM; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; PAN TROGLODYTES; PARANOID DISORDERS; PHENOTHIAZINES; PSYCHOSES, ALCOHOLIC; PSYCHOSES, SUBSTANCE-INDUCED; RATS; RECEPTORS, DRUG; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; SYNAPTIC TRANSMISSION;

EID: 0015383552     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1972.01750260021004     Document Type: Article

References (86)

1. Von Mering O, Moromito K, Hyde RW, et al: Experimentally induced depersonalization, in Hoch PH, Zubin J (eds): Experimental Psychopathology. New York, Grune & Stratton Inc, 1957, p 66.
2. Greiner T, Burch NR, Edelbert R: Psychopathology and psychophysiology of minimal LSD-25 dosage: A preliminary dosageresponse specrum. Arch Neurol Psychiat 79:208-210, 1958.
3. Hollister LE: Drug-induced psychoses and schizophrenic reactions: A critical comparison. Ann NY Acad Sci 96:80-88, 1962.
4. Bowers MB Jr, Freedman DX: “Psychedelic” experiences in acute psychoses. Arch Gen Psychiat 15:240-248, 1966.
5. Connell PH: Amphetamine Psychosis. London, Chapman & Hall Ltd, 1958.
6. Bell DS: Comparison of amphetamine psychosis and schizophrenia. Brit J Psychiat 111:701-707, 1965.
7. Beamish P, Kiloh LG: Psychoses due to amphetamine consumption. J Ment Sci 106:337-343, 1960.
8. Ellinwood EH Jr: Amphetamine psychosis: Individuals, settings, and sequences, in Ellinwood EH Jr, Cohen S (eds): Amphetamine Abuse. To be published.
9. Ellinwood EH Jr: Amphetamine psychosis: I. Description of the individuals and process. J Nerv Ment Dis 144:273-283, 1967.
10. Griffith JD, Cavanaugh JH, Held J, et al: Experimental psychosis induced by the administration of d-amphetamine, in Costa E, Garattini S (eds): Amphetamines and Related Compounds. New York, Raven Press, 1970, pp 897-904.
11. Angrist BM, Gershon S: The phenomenology of experimentally induced amphetamine psychosis: Preliminary observations. Biol Psychiat 2:95-107, 1970.
12. Rylander G: Clinical and medico-criminological aspects of addictions to central stimulating drugs, in Sjoqvist F, Tottie M (eds): Abuse of Central Stimulants. New York, Raven Press, 1969, pp 251-273.
13. Herman M, Nagler SH: Psychoses due to amphetamine. J Nerv Ment Dis 120:268-272, 1954.
14. Kalant OJ: The Amphetamines-Toxicity and Addiction. Toronto, University of Toronto Press, 1966.
15. Slater E: Amphetamine Psychosis by PH Connell, book review. Brit Med J 1:488, 1959.
16. Chapman J: The early symptoms of schizophrenia. Brit J Psychiat 112:225-251, 1966.
17. Mayer-Gross W, Slater E, Roth M: Clinical Psychiatry. Baltimore, Williams & Wilkins Co, 1960, p 377.
18. Ellinwood EH Jr: Chronic methamphetamine intoxication in three experimental animals, in Ellinwood EH Jr, Cohen S (eds): Amphetamine Abuse. To be published.
19. Askevold F: The occurrence of paranoid incidents and abstinence delirium in abusers of amphetamine. Acta Psychiat Neurol Scand 34:145-164, 1959.
20. Angrist BM, Schweitzer J, Friedhoff AJ, et al: The clinical symptomatology of amphetamine psychosis and its relationship to amphetamine levels in urine. Int Pharmacopsychiat 2:125-139, 1969.
21. Young GG, Simpson CB, Frohman CE: Clinical and biochemical studies of an amphetamine withdrawal psychosis. J Nerv Ment Dis 132:234-238, 1961.
22. Klein DF, Davis JM: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams & Wilkins Co, 1969, pp 52-138.
23. Jannsen AJ: The evolution of the butyrohenones haloperidol and trifluperidol from meperidine-like 4-phenylpiperidines. Int Rev Neurobiol 8:221-263, 1965.
24. Espelin DE, Done AK: Amphetamine poisoning: Effectiveness of chlorpromazine. New Eng J Med 278:1361-1365, 1968.
25. Sargent W, Slater E: An Introduction to Physical Methods of Treatment in Psychiatry. London, Livingston Publishing Co, 1954, p 203.
26. Hoff EC: Brain syndromes associated with drug or poison intoxication, in Freedman AM, Kaplan HE (eds): Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins Co, 1967, pp 759-774.
27. Levin M: Toxic psychoses, in Arietti S (ed): American Handbook of Psychiatry. New York, Basic Books Inc Publishers, 1959, p 1222.
28. Chafetz ME: Alcoholism, in Freedman AM, Kaplan HI (eds): Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins Co, 1967, pp 1011-1026.
29. Chloden LW, Kurland A, Savage C: Clinical reactions and tolerance to LSD in chronic schizophrenia. J Nerv Ment Dis 122:211-221, 1955.
30. Snyder SH, Lamparella V: Psychedelic experiences in hysterical psychosis and schizophrenia. Comm Behav Biol 3A:85-92, 1969.
31. McDowell FH: Psychiatric aspects of L-DOPA treatment in Parkinson's disease, in Barbeau A, McDowell FH (eds): L-DOPA and Parkinsonism. Philadelphia, FA Davis Co, 1970, p 321.
32. Celesia GG, Barr AN: Psychosis and other psychiatric manifestations of Levodopa therapy. Arch Neurol 23:193-200, 1970.
33. Goodwin FK, Murphy DL, Brodie HKH, et al: L-dopa, catecholamines and behavior: A clinical and biochemical study in depressed patients. Biol Psychiat 2:341-366, 1970.
34. Shader RI, DiMascio A: Psychotropic Drug Side Effects. Baltimore, Williams & Wilkins Co, 1970, pp 142-148.
35. Freud S: On the general effects of cocaine. Drug Dependence 5:15-17, 1970.
36. Bleuler E: Textbook of Psychiatry. New York, MacMillan Co Publishers, 1924, p 359.
37. Young D, Scoville WB: Paranoid psychosis in narcolepsy and the possible danger of Benzedrine treatment. Med Clin N Amer 22:637-645, 1938.
38. Chapman AH: Paranoid psychoses associated with amphetamine usage: A clinical note. Amer J Psychiat 111:43-45, 1954.
39. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington, the Association, 1952, vol 1, p 28.
40. Cameron N: Paranoid conditions and paranoia, in Arieti S (ed): American Handbook of Psychiatry. New York, Basic Books Inc, 1959, vol 1 p 510.
41. Redlich FC, Freedman DX: The Theory and Practice of Psychiatry. New York, Basic Books Inc, 1966, p 485.
42. Kallman SJ: Genetics of Schizophrenia. New York, JJ Augustin Inc Publishers, 1938.
43. Gottesman II, Shields J: A posygenic theory of schizophrenia. Proc Nat Acad Sci USA 58:199-205, 1967.
44. Schildkraut JJ, Kety SS: Biogenic amines and emotion. Science 156:21-30, 1967.
45. Hillarp NA, Fuxe K, Dahlstrom A: Demonstration and mapping of central neurons containing dopamine, noradrenaline and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol Rev 18:727-742, 1966.
46. Ungerstedt U: Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand 367(suppl):1-48, 1971.
47. Hornykiewicz O: Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 15:925-964, 1966.
48. Kamberi IA, Schneider HPG, McCann SM: Action of dopamine to induce release of FSH-releasing factor (FRF) from hypothalamic tissue in vitro. Endocrinology 86:278-284, 1970.
49. Olds J: Hypothalamic substrates of reward. Physiol Rev 42:554-604, 1962.
50. Stein L: Self-stimulation of the brain and the central stimulant action of amphetamine. Fed Proc 23:836-850, 1964.
51. Wise CD, Stein L: Facilitation of brain self-stimulation by central administration of norepinephrine. Science 163:299-301, 1969.
52. Bradley PB, Elkes J: The effect of drugs on the electrical activity of the brain. Brain 80:77-117, 1957.
53. Cotzias GC, Papavasiliou PS, Gellene R: Modification of parkinsonism: Chronic treatment with L-dopa. New Eng J Med 280:337-345, 1969.
54. Yahr M, Duvoisin RC, Schear MJ, et al: Treatment of parkinsonism with levodopa. Arch Neurol 21:343-354, 1969.
55. Barbeau A: L-dopa therapy in Parkinson's disease: A critical review of nine years' experience. Canad Med Assoc J 101:791-800, 1969.
56. Doshay LJ: Parkinsonism and Its Treatment. Philadelphia, JB Lippincott Co, 1954.
57. Friedman A, Everett G: Pharmacological aspects of parkinsonism. Advances Pharmacol 3:83-127, 1964.
58. Coyle JT, Snyder SH: Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 166:899-901, 1969.
59. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol 20:140-144, 1963.
60. Nyback H, Borzecki Z, Sedvall G: Accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain: Effect of some psychotropic drugs. Europ J Pharmacol 4:395-403, 1968.
61. Anden NE, Butcher SC, Corrodi H, et al: Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Europ J Pharmacol 11:303-314, 1970.
62. Yeh BK, McNay JL, Goldberg LI: Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: Evidence for a specific dopamine receptor. J Pharmacol Exp Ther 168:303-309, 1969.
63. Horn AS, Snyder SH: Chlorpromazine and dopamine: Conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc Nat Acad Sci USA 68:2325-2328, 1971.
64. Jannsen AJ: The evolution of the butyrophenones haloperidol and trifluperidol from meperidine-like 4-phenylpiperidines. Int Rev Neurobiol 8:221-263, 1965.
65. Von Rossum JM: The significance of dopamine receptor blockade for the action of neuroleptic drugs, in Brill H (ed): Neuropsychopharmacology. The Hague, Excerpta Medica Foundation, 1967, pp 321-329.
66. Tranzner JP, Thoenen H: An electron microscopic study of selective, acute degeneration of sympathetic nerve terminals after administration of 6-hydroxydopamine. Experientia 24:155-156, 1968.
67. Ungerstedt U: Histochemical studies on the effect of intercerebral and intraventricular injections of 6-hydroxydopamine on monoamine neurons in the rat brain, in Malmfors T, Thoenen H (eds): 6-Hydroxydopamine and Catecholamine Neurons. Amsterdam, Elsevier Pub Co, 1971, pp 101-127.
68. Coyle JT, Snyder SH: Catecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas. J Pharmacol Exp Ther 170:221-231, 1969.
69. Taylor KM, Snyder SH: Amphetamine: Differentiation by dand i-isomers of animal behavior involving central norepinephrine or dopamine. Science 168:1487-1489, 1970.
70. Taylor KM, Snyder SH: Differential effects of d-and i-amphetamine on behavior and on catecholamine disposition in dopamine and norepinephrine containing neurons of rat brain. Brain Res 28:295-309, 1971.
71. Snyder SH, Taylor KM, Coyle JT, et al: The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Amer J Psychiat 127:199-207, 1970.
72. Wolf HH: The importance of endogenous catecholamines in the activity of some CNS stimulants. Int J Neuropharmacol 8:319-328, 1969.
73. Rech RH: Antagonism of reserpine behavioral depression by d-amphetamine. J Pharmacol Exp Ther 146:369-376, 1964.
74. Carlsson A: Amphetamine and brain catecholamines, in Costa E, Garattini S (eds): Amphetamines and Related Compounds. New York, Raven Press, 1970, pp 289-300.
75. Randrup A, Munkvad I: Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia 11:300-310, 1967.
76. Fitzgerald F: Effects of d-amphetamine upon behavior of young chimpanzees reared under different conditions, in Brill H, Cole J (eds): Neuropsychopharmacology. Amsterdam, Exerpta Medica Foundation, 1967.
77. Randrup A, Scheel-Kruger J: Diethyldithiocarbamate and amphetamine stereotype behavior. J Pharm Pharmacol 18:752, 1966.
78. Randrup A, Munkvad I: Biochemical, anatomical and psychological investigations of stereotyped behavior induced by amphetamines, in Costa E, Garaattini S (eds): Amphetamines and Related Compounds. New York, Raven Press, 1970, pp 695-713.
79. McKenzie GM: Role of the tuberculum olfactorium in stereotyped behavior induced by apomorphine in the rat. Psychopharmacologia 23:212-220, 1972.
80. Fuxe K: Amphetamine-induced stereotyped behavior and central catecholamine neurons, in Sjoqvist F, Tottie M (eds): Abuse of Central Stimulants. New York, Raven Press, 1969, pp 450-451.
81. Ernst AM, Smelik P: Site of action of dopamine and apomorphine in compulsive gnawing behavior in rats. Experientia 22:837-839, 1966.
82. Fog RL, Randrup A, Pakkenberg H: Aminergic mechanisms in corpus striatum and amphetamine-induced stereotyped behavior. Psychopharmacologia 11:179-183, 1967.
83. Simpson BA, Iversen SD: Effects of substantia nigra lesions on the locomotor and stereotype responses to amphetamine. Nature 230:30-32, 1971.
84. Angrist BM, Shopsin B, Gershon S: The comparative psychotomimetic effects of stereoisomers of amphetamine. Nature 234:152-154, 1971.
85. Prinzmetal M, Alles GA: The central nervous system stimulant effects of dextro-amphetamine sulphate. JAMA 200:665-673, 1940.
86. Rimon R, Roos BE, Rakkolainen V, et al: The content of 5hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia. J Psychosom Res 15:375-378, 1971.